PharMerica serves bidder a poison pill

Share this article:

Just days after rejecting a $456 million purchase offer, the board at PharMerica Corp. adopted a poison-pill defense. The measure is intended to prevent Omnicare Inc. from obtaining control of PharMerica “in a manner or on terms that are not in the best interests of the company," according to the firm. The maneuver trades rights with PharMerica common stock. These rights would be exercisable should a person or group amass 15% or more of the company's common stock without board approval or announces a tender offer that attempts to do so. The companies are the two largest providers of pharmaceutical services in the long-term care sector.

Share this article:

More in Products

Stents safe for stroke prevention, study says

Placing a stent to keep a neck artery open is as effective as invasive neck surgery for long-term prevention of strokes, according to results from a European trial.

Honeywell Introduces remote patient monitor

Honeywell Introduces remote patient monitor

Honeywell has launched the HomMed Genesis DM™ v4.15, a new version of the remote patient monitor with new peripheral devices.

NKF launches interactive nutrition portal

NKF launches interactive nutrition portal

The National Kidney Foundation has debuted My Food Coach, an interactive nutrition panel meant to allow people to easily manage nutritional requirements.